Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
GLP-1 receptor agonists have transformed type 2 diabetes and obesity management, but the cost-effectiveness of GLP-1 therapies is now at the center of payer and policy debates. With drugs like semaglutide, liraglutide, dulaglutide, and tirzepatide expanding beyond glycemic control into cardiovascular and weight management, a key question remains: do their …
Read More »GLP-1s and Health Economics: Are They Cost-Effective in High-Risk Populations?
